Metal-Based Nanoparticles for Cancer Metalloimmunotherapy DOI Creative Commons
I. Suliman, K. H. Kim, Weihsuan Chen

et al.

Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(7), P. 2003 - 2003

Published: July 21, 2023

Although the promise of cancer immunotherapy has been partially fulfilled with unprecedented clinical success several immunotherapeutic interventions, some issues, such as limited response rate and immunotoxicity, still remain. Metalloimmunotherapy offers a new form that utilizes inherent immunomodulatory features metal ions to enhance anticancer immune responses. Their versatile functionalities for multitude direct indirect activities together their biocompatibility suggest can help overcome current issues associated immunotherapy. However, exhibit poor drug-like properties due intrinsic physicochemical profiles impede in vivo pharmacological performance, thus necessitating an effective pharmaceutical formulation strategy improve behavior. Metal-based nanoparticles provide promising platform technology reshaping into more formulations nano-enabled engineering approaches. This review provides general overview immunotherapy, system how it works against cells, role host modulation, well impact on process via regulation cells. The preclinical studies have demonstrated potential metal-based metalloimmunotherapy are presented representative constructed manganese, zinc, iron, copper, calcium, sodium ions. Lastly, perspectives future directions discussed, particularly respect applications.

Language: Английский

Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition DOI Creative Commons
Antonino Glaviano,

Hannah Lau,

Lukas M. Carter

et al.

Journal of Hematology & Oncology, Journal Year: 2025, Volume and Issue: 18(1)

Published: Jan. 13, 2025

The tumor microenvironment (TME) is integral to cancer progression, impacting metastasis and treatment response. It consists of diverse cell types, extracellular matrix components, signaling molecules that interact promote growth therapeutic resistance. Elucidating the intricate interactions between cells TME crucial in understanding progression challenges. A critical process induced by epithelial-mesenchymal transition (EMT), wherein epithelial acquire mesenchymal traits, which enhance their motility invasiveness progression. By targeting various components TME, novel investigational strategies aim disrupt TME's contribution EMT, thereby improving efficacy, addressing resistance, offering a nuanced approach therapy. This review scrutinizes key players emphasizing avenues therapeutically components. Moreover, article discusses implications for resistance mechanisms highlights current toward modulation along with potential caveats.

Language: Английский

Citations

16
Molecular and metabolic regulation of immunosuppression in metastatic pancreatic ductal adenocarcinoma DOI Creative Commons
Shailendra K. Gautam, Surinder K. Batra, Maneesh Jain

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: July 24, 2023

Immunosuppression is a hallmark of pancreatic ductal adenocarcinoma (PDAC), contributing to early metastasis and poor patient survival. Compared the localized tumors, current standard-of-care therapies have failed improve survival patients with metastatic PDAC, that necessecitates exploration novel therapeutic approaches. While immunotherapies such as immune checkpoint blockade (ICB) vaccines emerged promising treatment modalities in certain cancers, limited responses been achieved PDAC. Therefore, specific mechanisms regulating response immunotherapy must be explored. The immunosuppressive microenvironment driven by oncogenic mutations, tumor secretome, non-coding RNAs, microbiome persists throughout PDAC progression, allowing neoplastic cells grow locally metastasize distantly. escaping host surveillance are unique molecular, immunological, metabolic characteristics. Following chemokine exosomal guidance, these organ-specific pre-metastatic niches (PMNs) constituted local resident cells, stromal fibroblasts, suppressive metastasis-associated macrophages, neutrophils, myeloid-derived suppressor cells. differs from primary tumors cell composition, functionality, metabolism. Thus far, multiple molecular pathways, distinct identified dampen effector functions, confounding This review describes major immunoregulatory pathways contribute progression limit outcomes Overall, we highlight vulnerabilities attributable factors discuss whether targeting immunological "hot spots" could immunotherapies.

Language: Английский

Citations

41
The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy DOI Creative Commons
Xuan Jiang,

Xiaofang Wu,

Yuxi Xiao

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Jan. 27, 2023

Hematological malignancy develops and applies various mechanisms to induce immune escape, in part through an immunosuppressive microenvironment. Adenosine is metabolite produced at high levels within the tumor microenvironment (TME). signaling A 2A receptor expressed on cells, such as T potently dampens responses. Extracellular adenosine generated by ectonucleoside triphosphate diphosphohydrolase-1 (CD39) ecto-5’-nucleotidase (CD73) molecules a newly recognized ‘immune checkpoint mediator’ leads identification of essential regulator hematological malignancies. In this Review, we provide overview detailed distribution function CD39 CD73 ectoenzymes TME effects inhibition preclinical data, which provides insights into potential clinical applications for immunotherapy.

Language: Английский

Citations

31
Unraveling the enigma of tumor-associated macrophages: challenges, innovations, and the path to therapeutic breakthroughs DOI Creative Commons
Shengwen Shao, Huilai Miao, Wenxue Ma

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Nov. 14, 2023

Tumor-associated macrophages (TAMs) are integral to the tumor microenvironment (TME), influencing cancer progression significantly. Attracted by cell signals, TAMs exhibit unparalleled adaptability, aligning with dynamic milieu. Their roles span from promoting growth and angiogenesis modulating metastasis. While substantial research has explored fundamentals of TAMs, comprehending their adaptive behavior, leveraging it for novel treatments remains challenging. This review delves into TAM polarization, metabolic shifts, complex orchestration cytokines chemokines determining functions. We highlight complexities TAM-targeted focusing on adaptability potential variability in therapeutic outcomes. Moreover, we discuss synergy integrating TAM-focused strategies established treatments, such as chemotherapy, immunotherapy. Emphasis is laid pioneering methods like reprogramming immunotherapy adoption single-cell technologies precision intervention. synthesis seeks shed light TAMs’ multifaceted cancer, pinpointing prospective pathways transformative enhancing modalities oncology.

Language: Английский

Citations

30
Immunogenic cell death in cancer immunotherapy DOI Creative Commons

Minji Choi,

Jisoo Shin,

Chae-Eun Lee

et al.

BMB Reports, Journal Year: 2023, Volume and Issue: 56(5), P. 275 - 286

Published: March 10, 2023

Cancer immunotherapy has been acknowledged as a new paradigm for cancer treatment, with notable therapeutic effects on certain types. Despite their significant potential, clinical studies over the past decade have revealed that low response rates in majority of solid tumors. One key causes poor responses is known to be relatively immunogenicity Because most tumors are immune desert 'cold tumors' antitumor immunity blocked from onset innate immunity, combination therapies combine validated T-based approaches can increase tumor-immunogenicity being considered relevant options. This review paper focuses immunogenic cell death (ICD) way enhancing tumor tissues. We will thoroughly how ICDs such necroptosis, pyroptosis, and ferroptosis improve anti-tumor outline trials targeting ICD. Finally, we discuss potential ICD inducers. an adjuvant immunotherapy.[BMB Reports 2023; 56(5): 275-286].

Language: Английский

Citations

24
Potential role of p53 deregulation in modulating immune responses in human malignancies: A paradigm to develop immunotherapy DOI

Shivi Chauhan,

Shivani Jaiswal, Vibhuti Jakhmola

et al.

Cancer Letters, Journal Year: 2024, Volume and Issue: 588, P. 216766 - 216766

Published: Feb. 25, 2024

Language: Английский

Citations

12
Implications of nanotherapeutic advancements to leverage multi-drug resistant breast cancer: The state-of-the-art review DOI Creative Commons

Adhithya Aravindan,

Ashutosh Gupta, Sudheer Moorkoth

et al.

Journal of Drug Delivery Science and Technology, Journal Year: 2024, Volume and Issue: 100, P. 106007 - 106007

Published: Aug. 5, 2024

Globally, cancer is regarded as a severe health issue. Among these breast (BC), the second most common kind in women after skin cancer. According to statistical data from NIH Cancer Institute, expected number of cases was around 3 lakh people, with 7.1 % fatality rate. The rise multidrug resistance (MDR) British Columbia issue it lowers effectiveness existing treatments. Traditional MDR treatment approaches BC have drawbacks, including toxicity, high cost, early discharge, restricted drug load before target, and poor effectiveness. Preventing has depended heavily on developing innovative therapy delivery methods utilizing nanomedicine new diagnosing treating BC. This review discusses its pathophysiology relation tumor kinetics. It focuses latest therapeutic over traditional like Surgery, Chemotherapy, Nanomedicine, Phototherapy, Immunotherapy, Gene therapy. also describes diagnostic techniques using MRI/PET, Mammography, Microwave Sensing, In-silico methods, Molecular techniques, AI-machine learning-based tools. discussed limitations nanoparticles article aims identify efficient ways diagnose treat prevent recurrence.

Language: Английский

Citations

11
Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens DOI Creative Commons
Nityanand Srivastava, Salman Sadullah Usmani,

Rajasekaran Subbarayan

et al.

Frontiers in Oncology, Journal Year: 2023, Volume and Issue: 13

Published: July 10, 2023

Triple-negative breast cancer (TNBC) is one of the deadliest subtypes (BC) for its high aggressiveness, heterogeneity, and hypoxic nature. Based on biological clinical observations TNBC related mortality very worldwide. Emerging studies have clearly demonstrated that hypoxia regulates critical metabolic, developmental, survival pathways in TNBC, which include glycolysis angiogenesis. Alterations to these accelerate stem cells (CSCs) enrichment immune escape, further lead tumor invasion, migration, metastasis. Beside this, also manipulates epigenetic plasticity DNA damage response (DDR) syndicate progression. Hypoxia fundamentally creates low oxygen condition responsible alteration Hypoxia-Inducible Factor-1alpha (HIF-1α) signaling within microenvironment, allowing tumors survive making them resistant various therapies. Therefore, there an urgent need society establish target-based therapies overcome resistance limitations current treatment plan TNBC. In this review article, we thoroughly discussed plausible significance HIF-1α as a target therapeutic regimens such chemotherapy, radiotherapy, immunotherapy, anti-angiogenic therapy, adjuvant therapy photodynamic adoptive cell combination therapies, antibody drug conjugates vaccines. Further, reviewed here intrinsic mechanism existing issues targeting while improvising strategies. This highlights discusses future perspectives major alternatives by hypoxia-induced signaling.

Language: Английский

Citations

23
Mechanism of M2 type macrophage-derived extracellular vesicles regulating PD-L1 expression via the MISP/IQGAP1 axis in hepatocellular carcinoma immunotherapy resistance DOI

Xiaobo Wang,

Xuxing Ye,

Yanping Chen

et al.

International Immunopharmacology, Journal Year: 2023, Volume and Issue: 124, P. 110848 - 110848

Published: Aug. 24, 2023

Language: Английский

Citations

21
Lactate acidosis and simultaneous recruitment of TGF-β leads to alter plasticity of hypoxic cancer cells in tumor microenvironment DOI
Saumya Rastogi, Shashank Shekher Mishra, Mandeep Kumar Arora

et al.

Pharmacology & Therapeutics, Journal Year: 2023, Volume and Issue: 250, P. 108519 - 108519

Published: Aug. 23, 2023

Language: Английский

Citations

20